STI-571 |
IMATINIB |
GLEEVEC |
CGP 57148 |
STI 571 |
ALPHA-(4-METHYL-1-PIPERAZINYL)-3'-{[4-(3-PYRIDYL)-2-PYRIMIDINYL]AMINO}-P-TOLUIDIDE |
QTI571 |
STI571 |
4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE |
chembl:CHEMBL941 |
chemidplus:152459-95-5 |
drugbank:00619 |
pubchem.compound:5291 |
rxcui:282388 |
Drug Class | Small Molecule |
Drug Indications | antineoplastic agent |
FDA Approval | approved |
Drug Class | antineoplastic agents, protein kinase inhibitors |
Year of Approval | 2001 |
Drug Class | Kinase Inhibitor |
FDA Approval | GI stromal tumor (KIT+), Dermatofibrosarcoma protuberans, Multiple hematologic malignancies including Philadelphia chromosome-positive ALL and CML |
Drug Class | Kinase Inhibitors |
Drug Categories | benzamides and benzamide derivatives |
Drug Categories | bsep/abcb11 substrates |
Drug Categories | cardiotoxic antineoplastic agents |
Drug Categories | cytochrome p-450 cyp2c8 substrates |
Drug Categories | cytochrome p-450 cyp2c9 inhibitors (moderate) |
Drug Categories | cytochrome p-450 cyp2c9 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 cyp3a5 inhibitors |
Drug Categories | cytochrome p-450 cyp3a5 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a5 substrates |
Drug Categories | cytochrome p-450 cyp3a7 inhibitors |
Drug Categories | cytochrome p-450 cyp3a7 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a7 substrates |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | drugs causing inadvertant photosensitivity |
Drug Categories | highest risk qtc-prolonging agents |
Drug Categories | kinase inhibitor |
Drug Categories | oct1 substrates |
Drug Categories | oct2 inhibitors |
Drug Categories | p-glycoprotein inhibitors |
Drug Categories | p-glycoprotein substrates |
Drug Categories | photosensitizing agents |
Drug Categories | qtc prolonging agents |
Drug Categories | tyrosine kinase inhibitors |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
multitarget |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Approval Status | Guideline |
Indication/Tumor Type | prostate neuroendocrine neoplasm |
Approval Status | Phase II |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Clinical Status | preclinical |
Pathway | activation |
Variant Effect | gain-of-function |
inhibitor (inhibitory) |
Fusion protein | BCR:ABL1 |
Trial Name | imatinib mesylate, STI 571,Gleevec, Glivec |
Novel drug target | Established target |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Drug family | BCR-ABL inhibitor 1st gen&KIT inhibitor |
Alteration | PDGFRB__COL1A1 |
Trial Name | imatinib mesylate, STI 571,Gleevec, Glivec |
inhibitor (inhibitory) |
Direct Interaction? | False |
Endogenous Drug? | False |
Specific Action of the Ligand | Inhibition |
n/a |
combination therapy | Trametinib;Imatinib |
Drug family | MEK inhibitor;BCR-ABL inhibitor 1st gen&KIT inhibitor |
Alteration | PRKCH:amp;ABL1__BCR |
inhibitor (inhibitory) |
Trial Name | imatinib mesylate, STI 571,Gleevec, Glivec |
Novel drug target | Established target |
n/a |
Drug family | BCR-ABL inhibitor 1st gen&KIT inhibitor |
Alteration | NF1:del |
Alteration | NF1:. |
n/a |
Drug family | BCR-ABL inhibitor 1st gen&KIT inhibitor |
Alteration | KRAS:G12. |
IMATINIB | DrugBank Drug Name |
152459-95-5 | CAS Number |
Ach-imatinib | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Categories | acids, carbocyclic |
CGP57148 | Development Name |
CGP57148B | Development Name |
IMATINIB | Generic Name |
Drug Class | Kinase Inhibitors |
FDA Approval | GI stromal tumor (KIT+), Dermatofibrosarcoma protuberans, Multiple hematologic malignancies including Philadelphia chromosome-positive ALL and CML |
Drug Class | Kinase Inhibitor |
IMATINIB | Primary Drug Name |
Year of Approval | 2001 |
Drug Class | antineoplastic agents, protein kinase inhibitors |
FDA Approval | approved |
Drug Indications | antineoplastic agent |
Drug Class | Small Molecule |
C1687 | NCI drug code |
CHEMBL941 | ChEMBL Drug ID |
C1687 | NCI drug code |
C1687 | NCI drug code |
IMATINIB | GuideToPharmacology Ligand Name |
D0AZ3C | TTD Drug ID |
IMATINIB | Primary Drug Name |
IMATINIB | Drug Generic Name |
GLEEVEC | Drug Trade Name |